S-1/A: Silexion Therapeutics Eyes $5 Million in Best-Efforts Offering to Advance Cancer Treatments

Silexion Therapeutics is launching a best-efforts offering to raise up to $5 million for advancing its RNAi-based cancer therapies.

Summary

• Silexion Therapeutics is seeking to raise up to $5 million through a best-efforts offering of ordinary shares and warrants.
• The offering includes ordinary shares and pre-funded warrants, each accompanied by ordinary warrants.
• The assumed public offering price is $1.94 per ordinary share and ordinary warrant, based on the closing price on January 10, 2025.
• The company intends to use the net proceeds to advance pre-clinical and clinical studies and for general corporate purposes.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering, which will terminate on February 1, 2025, unless terminated earlier.
• The company is registering up to 2,577,320 ordinary shares, pre-funded warrants for the same amount, and placement agent warrants for up to 180,412 ordinary shares.
• The company has two market value-related deficiencies with Nasdaq and has until May 19, 2025, to regain compliance.
• The company effected a 1-for-9 reverse share split on November 27, 2024.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is actively pursuing clinical trials and has potential in the oncology space, it faces significant financial challenges, including recurring losses and the need for additional funding. The Nasdaq compliance issues and the risks associated with the industry further contribute to a cautious sentiment.

Positives

• The company is actively developing a platform focused on silencing the KRAS oncogene using RNA-interference therapeutics.
• The company plans to initiate toxicology studies of SIL-204B in 2025 followed by the regulatory submission in the second half of 2025 to initiate the Phase 2/3 trial and trial initiation in the first half of 2026.
• The company held a meeting with the Federal Institute for Drugs and Medical Devices in Germany (BfArM) to discuss the planned design of the Phase 2/3 trial at which BfArM agreed, in principle, to the design.

Negatives

• The company has incurred net losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future.
• The company has substantial doubt about its ability to continue as a going concern.
• The approach the company is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• The company is heavily dependent on the success of its product candidates, which are in the early stages of preclinical or clinical development.
• The company faces intense competition and rapid technological change.
• The company may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success.
• The company may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide it only limited working capital.
• The company's management team will have immediate and broad discretion over the use of the net proceeds from this offering and may not use them effectively.
• The company's reverse share split may negatively impact the market for its ordinary shares.

Risks

• The company is a development-stage company and has a limited operating history.
• The company has never generated any revenue from product sales and may never be profitable.
• The company will need to raise substantial additional funding, which may not be available on acceptable terms, or at all, and which will cause dilution to its shareholders.
• The company's independent registered public accounting firms report contains an explanatory paragraph that expresses substantial doubt about its ability to continue as a going concern.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable.
• The company may find it difficult to enroll patients in its clinical studies, which could delay or prevent clinical studies of its product candidates.
• The company faces intense competition and rapid technological change and the possibility that its competitors may develop therapies that are similar, more advanced, or more effective than ours.
• If the company fails to maintain compliance with Nasdaqs continued listing requirements, its securities may be delisted from the Nasdaq Global Market.
• The company's management team will have immediate and broad discretion over the use of the net proceeds from this offering and may not use them effectively.
• The price of the company's ordinary shares and its warrants may be volatile.
• Conditions in the Middle East and in Israel may harm the company's operations.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future and will need to raise additional capital to finance its operations.

Industry Context

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. The company faces competition from other companies developing novel drugs and technology platforms using similar or competing technologies.

Stakeholder Impact

• Shareholders will experience immediate dilution in the book value per share of the ordinary shares purchased in the offering.
• The company may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds from this offering, which will provide it only limited working capital.

Next Steps

• The company plans to initiate toxicology studies of SIL-204B in 2025.
• The company plans to make a regulatory submission in the second half of 2025 to initiate the Phase 2/3 trial.
• The company plans to initiate the Phase 2/3 trial in the first half of 2026.

Key Dates

Keywords

Silexion Therapeutics, best-efforts offering, ordinary shares, pre-funded warrants, ordinary warrants, RNAi therapeutics, KRAS, cancer treatment, clinical trials, biotechnology, pharmaceutical, Nasdaq, SIL-204B, LAPC